A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China

Open Access

Peer-reviewed

Research Article

Wei Li ,

Roles Investigation, Methodology, Writing – original draft, Writing – review & editing

* E-mail: liwei1988hust@126.com

Affiliation Department of Pharmacy, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

https://orcid.org/0000-0001-9123-7908

⨯
Li Wan

Affiliation Department of Pharmacy, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
⨯

Reader Comments (0)

Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Cancer immunotherapy
Is the Subject Area "Cancer immunotherapy" applicable to this article?

Thanks for your feedback.
Non-small cell lung cancer
Is the Subject Area "Non-small cell lung cancer" applicable to this article?

Thanks for your feedback.
Chemoradiotherapy
Is the Subject Area "Chemoradiotherapy" applicable to this article?

Thanks for your feedback.
Curve fitting
Is the Subject Area "Curve fitting" applicable to this article?

Thanks for your feedback.
China
Is the Subject Area "China" applicable to this article?

Thanks for your feedback.
Cost-effectiveness analysis
Is the Subject Area "Cost-effectiveness analysis" applicable to this article?

Thanks for your feedback.
Health economics
Is the Subject Area "Health economics" applicable to this article?

Thanks for your feedback.